Cargando…
Development of an adenosquamous carcinoma histopathology – selective lung metastasis model
Preclinical tumor models with native tissue microenvironments provide essential tools to understand how heterogeneous tumor phenotypes relate to drug response. Here we present syngeneic graft models of aggressive, metastasis-prone histopathology-specific NSCLC tumor types driven by KRAS mutation and...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770245/ https://www.ncbi.nlm.nih.gov/pubmed/36355420 http://dx.doi.org/10.1242/bio.059623 |
_version_ | 1784854551046651904 |
---|---|
author | Lähdeniemi, Iris A. K. Devlin, Jennifer R. Nagaraj, Ashwini S. Talwelkar, Sarang S. Bao, Jie Linnavirta, Nora Şeref Vujaklija, Ceren Kiss, Elina A. Hemmes, Annabrita Verschuren, Emmy W. |
author_facet | Lähdeniemi, Iris A. K. Devlin, Jennifer R. Nagaraj, Ashwini S. Talwelkar, Sarang S. Bao, Jie Linnavirta, Nora Şeref Vujaklija, Ceren Kiss, Elina A. Hemmes, Annabrita Verschuren, Emmy W. |
author_sort | Lähdeniemi, Iris A. K. |
collection | PubMed |
description | Preclinical tumor models with native tissue microenvironments provide essential tools to understand how heterogeneous tumor phenotypes relate to drug response. Here we present syngeneic graft models of aggressive, metastasis-prone histopathology-specific NSCLC tumor types driven by KRAS mutation and loss of LKB1 (KL): adenosquamous carcinoma (ASC) and adenocarcinoma (AC). We show that subcutaneous injection of primary KL; ASC cells results in squamous cell carcinoma (SCC) tumors with high levels of stromal infiltrates, lacking the source heterogeneous histotype. Despite forming subcutaneous tumors, intravenously injected KL;AC cells were unable to form lung tumors. In contrast, intravenous injection of KL;ASC cells leads to their lung re-colonization and lesions recapitulating the mixed AC and SCC histopathology, tumor immune suppressive microenvironment and oncogenic signaling profile of source tumors, demonstrating histopathology-selective phenotypic dominance over genetic drivers. Pan-ERBB inhibition increased survival, while selective ERBB1/EGFR inhibition did not, suggesting a role of the ERBB network crosstalk in resistance to ERBB1/EGFR. This immunocompetent NSCLC lung colonization model hence phenocopies key properties of the metastasis-prone ASC histopathology, and serves as a preclinical model to dissect therapy responses and metastasis-associated processes. |
format | Online Article Text |
id | pubmed-9770245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Company of Biologists Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-97702452022-12-22 Development of an adenosquamous carcinoma histopathology – selective lung metastasis model Lähdeniemi, Iris A. K. Devlin, Jennifer R. Nagaraj, Ashwini S. Talwelkar, Sarang S. Bao, Jie Linnavirta, Nora Şeref Vujaklija, Ceren Kiss, Elina A. Hemmes, Annabrita Verschuren, Emmy W. Biol Open Research Article Preclinical tumor models with native tissue microenvironments provide essential tools to understand how heterogeneous tumor phenotypes relate to drug response. Here we present syngeneic graft models of aggressive, metastasis-prone histopathology-specific NSCLC tumor types driven by KRAS mutation and loss of LKB1 (KL): adenosquamous carcinoma (ASC) and adenocarcinoma (AC). We show that subcutaneous injection of primary KL; ASC cells results in squamous cell carcinoma (SCC) tumors with high levels of stromal infiltrates, lacking the source heterogeneous histotype. Despite forming subcutaneous tumors, intravenously injected KL;AC cells were unable to form lung tumors. In contrast, intravenous injection of KL;ASC cells leads to their lung re-colonization and lesions recapitulating the mixed AC and SCC histopathology, tumor immune suppressive microenvironment and oncogenic signaling profile of source tumors, demonstrating histopathology-selective phenotypic dominance over genetic drivers. Pan-ERBB inhibition increased survival, while selective ERBB1/EGFR inhibition did not, suggesting a role of the ERBB network crosstalk in resistance to ERBB1/EGFR. This immunocompetent NSCLC lung colonization model hence phenocopies key properties of the metastasis-prone ASC histopathology, and serves as a preclinical model to dissect therapy responses and metastasis-associated processes. The Company of Biologists Ltd 2022-12-13 /pmc/articles/PMC9770245/ /pubmed/36355420 http://dx.doi.org/10.1242/bio.059623 Text en © 2022. Published by The Company of Biologists Ltd https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. |
spellingShingle | Research Article Lähdeniemi, Iris A. K. Devlin, Jennifer R. Nagaraj, Ashwini S. Talwelkar, Sarang S. Bao, Jie Linnavirta, Nora Şeref Vujaklija, Ceren Kiss, Elina A. Hemmes, Annabrita Verschuren, Emmy W. Development of an adenosquamous carcinoma histopathology – selective lung metastasis model |
title | Development of an adenosquamous carcinoma histopathology – selective lung metastasis model |
title_full | Development of an adenosquamous carcinoma histopathology – selective lung metastasis model |
title_fullStr | Development of an adenosquamous carcinoma histopathology – selective lung metastasis model |
title_full_unstemmed | Development of an adenosquamous carcinoma histopathology – selective lung metastasis model |
title_short | Development of an adenosquamous carcinoma histopathology – selective lung metastasis model |
title_sort | development of an adenosquamous carcinoma histopathology – selective lung metastasis model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770245/ https://www.ncbi.nlm.nih.gov/pubmed/36355420 http://dx.doi.org/10.1242/bio.059623 |
work_keys_str_mv | AT lahdeniemiirisak developmentofanadenosquamouscarcinomahistopathologyselectivelungmetastasismodel AT devlinjenniferr developmentofanadenosquamouscarcinomahistopathologyselectivelungmetastasismodel AT nagarajashwinis developmentofanadenosquamouscarcinomahistopathologyselectivelungmetastasismodel AT talwelkarsarangs developmentofanadenosquamouscarcinomahistopathologyselectivelungmetastasismodel AT baojie developmentofanadenosquamouscarcinomahistopathologyselectivelungmetastasismodel AT linnavirtanora developmentofanadenosquamouscarcinomahistopathologyselectivelungmetastasismodel AT serefvujaklijaceren developmentofanadenosquamouscarcinomahistopathologyselectivelungmetastasismodel AT kisselinaa developmentofanadenosquamouscarcinomahistopathologyselectivelungmetastasismodel AT hemmesannabrita developmentofanadenosquamouscarcinomahistopathologyselectivelungmetastasismodel AT verschurenemmyw developmentofanadenosquamouscarcinomahistopathologyselectivelungmetastasismodel |